Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Accumulated Depreciation (2016 - 2024)

Historic Accumulated Depreciation for Altimmune (ALT) over the last 11 years, with Q4 2024 value amounting to $2.2 million.

  • Altimmune's Accumulated Depreciation rose 1205.06% to $2.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.2 million, marking a year-over-year increase of 1205.06%. This contributed to the annual value of $2.2 million for FY2024, which is 1205.06% up from last year.
  • Latest data reveals that Altimmune reported Accumulated Depreciation of $2.2 million as of Q4 2024, which was up 1205.06% from $2.0 million recorded in Q4 2023.
  • Over the past 5 years, Altimmune's Accumulated Depreciation peaked at $2.2 million during Q4 2024, and registered a low of $1.1 million during Q1 2022.
  • For the 5-year period, Altimmune's Accumulated Depreciation averaged around $1.8 million, with its median value being $1.8 million (2021).
  • In the last 5 years, Altimmune's Accumulated Depreciation plummeted by 3608.36% in 2022 and then soared by 3184.25% in 2023.
  • Over the past 5 years, Altimmune's Accumulated Depreciation (Quarter) stood at $1.6 million in 2020, then increased by 28.03% to $2.0 million in 2021, then decreased by 26.82% to $1.5 million in 2022, then surged by 31.84% to $2.0 million in 2023, then grew by 12.05% to $2.2 million in 2024.
  • Its Accumulated Depreciation was $2.2 million in Q4 2024, compared to $2.0 million in Q4 2023 and $1.5 million in Q4 2022.